Metabolism, Excretion, and Pharmacokinetics of Rosuvastatin in Healthy Adult Male Volunteers

Clinical Therapeutics

Volumn 25, Issue 11, 2003, Pages 2822-2835

  Martin, Paul D ^a   Warwick, Mike J ^a   Dane, Aaron L ^a   Hill, Steve J ^a   Giles, Petrina B ^a   Phillips, Paul J ^a   Lenz, Eva ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Excretion; HMG CoA reductase inhibitor; Metabolism; Pharmacokinetics; Rosuvastatin

Indexed keywords

DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NORROSUVASTATIN; ROSUVASTATIN; ROSUVASTATIN 5 LACTONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; FECES; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE; OPEN STUDY; PHARYNGITIS; RADIOACTIVITY; SINGLE DRUG DOSE; URINARY EXCRETION; VOLUNTEER;

EID: 0344664550     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80336-3     Document Type: Article

References (21)

1. Chapman MJ, McTaggart F. Optimizing the pharmacology of statins: Characteristics of rosuvastatin. Atheroscler Suppl. 2002;2:33-36.
2. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002;144:1044-1051.
3. Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J. 2002;144:1036-1043.
4. Blasetto JW, Stein EA, Brown WV, et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol. 2003;91:3C-10C.
5. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol. 2003;93:152-160.
6. Olsson AG, McTaggart F, Raza A. Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002;20:303-328.
7. Schuster H. Rosuvastatin - a highly effective new HMG-CoA reductase inhibitor: Review of clinical trial data at 10 mg to 40 mg doses in dyslipidemic patients. Cardiology. In press.
8. Nezasa K, Higaki K, Matsumura T, et al. Liver-specific distribution of rosuvastatin in rats: Comparison with pravastatin and simvastatin. Drug Metab Dispos. 2002;30:1158-1163.
9. Nezasa K, Higaki K, Takeuchi M, et al. Uptake of rosuvastatin by isolated rat hepatocytes: Comparison with pravastatin. Xenobiotica. 2003;33:379-388.
10. Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Atheroscler Suppl. 2001;2:90. Abstract P174.
11. Cooper KJ, Martin PD, Dane AL, et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002;58:527-531.
12. Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol. 2003;55:94-99.
13. Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2003;73:322-329.
14. Cooper KJ, Martin PD, Dane AL, et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2003;59:51-56.
15. Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor. J Clin Pharmacol. 2002;42:1116-1121.
16. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002;54:472-477.
17. Martin PD, Warwick MJ, Dane AL, Cantarini MV. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther. 2003;25:2215-2224.
18. Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin. Clin Ther. 2003;25:2553-2563.
19. McCormick AD, McKillop D, Butters CJ, et al. ZD4522 - an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems. J Clin Pharmacol. 2000;40:1055. Abstract 46.
20. Hull CK, Penman AD, Smith CK, Martin PD. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;772:219-228.
21. Martin J, Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: Are they clinically relevant? Drug Saf. 2003;26:13-21.